Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
API
0
FDF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Gyno-trosyd
2. Monistat 1-day
3. Mykontral
4. Trosderm
5. Trosid
6. Trosyd
7. Trosyl
8. Uk 20,349
9. Vagistat
10. Vagistat-1
1. 65899-73-2
2. Vagistat
3. Vagistat-1
4. Trosyd
5. Trosyl
6. Gyno-trosyd
7. Fungibacid
8. Zoniden
9. Tioconazol [inn-spanish]
10. Tioconazolum [inn-latin]
11. Uk-20349
12. 1-(2-((2-chlorothiophen-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1h-imidazole
13. Uk-20,349
14. Tioconazolum
15. Nsc-759169
16. 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
17. Tioconazol
18. Chebi:77898
19. Mfcd00057276
20. S57y5x1117
21. Ncgc00167430-01
22. Tz-3
23. 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole
24. 1-{2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1h-imidazole
25. 1h-imidazole, 1-(2-((2-chloro-3-thienyl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-
26. Dsstox_cid_26619
27. Dsstox_rid_81771
28. Dsstox_gsid_46619
29. New Straitus
30. 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
31. Smr001550005
32. (+-)-tioconazole
33. Cas-65899-73-2
34. Vagistat-1 (tn)
35. Uk 20349
36. Sr-05000001939
37. Einecs 265-973-8
38. Brn 0573867
39. Tioconazole (jan/usp/inn)
40. Unii-s57y5x1117
41. 1h-imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-
42. 1-[(2s)-2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
43. 1-(2,4-dichloro-beta-((2-chloro-3-thenyl)-oxy)phenethyl)imidazole
44. (+-)-1-(2,4-dichloro-beta-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole
45. Tioconazole, 97%
46. Tioconazole [usan:usp:inn:ban:jan]
47. Tioconazole [mi]
48. 1-(2,4-dichloro-(beta-(2-chloro-3-thenyl)oxy)phenethyl)imidazole
49. Tioconazole [inn]
50. Tioconazole [jan]
51. (.+/-.)-tioconazole
52. Tioconazole [inci]
53. Tioconazole [usan]
54. Tioconazole [vandf]
55. Tioconazole [mart.]
56. Schembl41354
57. Tioconazole [usp-rs]
58. Tioconazole [who-dd]
59. 5-23-04-00324 (beilstein Handbook Reference)
60. Mls003899209
61. Mls004712040
62. Mls006010907
63. Chembl1200438
64. Dtxsid3046619
65. Tioconazole [orange Book]
66. Tioconazole For System Suitability
67. Hms2090b12
68. Hms2093p11
69. Hms3655k22
70. Hms3712i10
71. Pharmakon1600-01505581
72. Tioconazole [ep Monograph]
73. Tioconazole [usp Impurity]
74. Tioconazole [usp Monograph]
75. Amy32535
76. Hy-b0319
77. Tox21_112434
78. Bdbm50370218
79. Dl-515
80. Nsc759169
81. S1910
82. Akos015906500
83. Tox21_112434_1
84. Ccg-213487
85. Db01007
86. Ks-5114
87. Nsc 759169
88. (+-)-1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1h-imidazole
89. Ncgc00167430-02
90. Ncgc00167430-03
91. Ncgc00167430-04
92. Ac-13425
93. Ac-31721
94. Sbi-0206824.p001
95. Ft-0630756
96. Sw198590-2
97. C08082
98. D00890
99. D83125
100. Ab01275523-01
101. Ab01275523_02
102. Ab01275523_03
103. Tioconazole, Vetranal(tm), Analytical Standard
104. 899t732
105. A835270
106. Q260326
107. Sr-05000001939-1
108. Sr-05000001939-2
109. Brd-a33084557-001-01-7
110. Tioconazole, United States Pharmacopeia (usp) Reference Standard
111. 1-[2,4-dichloro-.beta.-[(2-chloro-3-thenyl)-oxy]phenethyl]imidazole
112. (.+/-.)-1-(2,4-dichloro-.beta.-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole
113. 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1h-imidazole #
114. 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1h-imidazole
115. Tioconazole For System Suitability, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 387.7 g/mol |
|---|---|
| Molecular Formula | C16H13Cl3N2OS |
| XLogP3 | 5.3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 385.981417 g/mol |
| Monoisotopic Mass | 385.981417 g/mol |
| Topological Polar Surface Area | 55.3 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 379 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Tioconazole |
| PubMed Health | Tioconazole (Topical route) |
| Drug Classes | Imidazole |
| Active Ingredient | Tioconazole |
| Dosage Form | Ointment |
| Route | Vaginal |
| Strength | 6.5% |
| Market Status | Over the Counter |
| Company | Perrigo |
| 2 of 4 | |
|---|---|
| Drug Name | Vagistat-1 |
| Active Ingredient | Tioconazole |
| Dosage Form | Ointment |
| Route | Vaginal |
| Strength | 6.5% |
| Market Status | Over the Counter |
| Company | Novartis |
| 3 of 4 | |
|---|---|
| Drug Name | Tioconazole |
| PubMed Health | Tioconazole (Topical route) |
| Drug Classes | Imidazole |
| Active Ingredient | Tioconazole |
| Dosage Form | Ointment |
| Route | Vaginal |
| Strength | 6.5% |
| Market Status | Over the Counter |
| Company | Perrigo |
| 4 of 4 | |
|---|---|
| Drug Name | Vagistat-1 |
| Active Ingredient | Tioconazole |
| Dosage Form | Ointment |
| Route | Vaginal |
| Strength | 6.5% |
| Market Status | Over the Counter |
| Company | Novartis |
For the local treatment of vulvovaginal candidiasis (moniliasis).
FDA Label
Tioconazole is a broad-spectrum imidazole antifungal agent that inhibits the growth of human pathogenic yeasts. Tioconazole exhibits fungicidal activity in vitro against Candida albicans, other species of the genus Candida, and against Torulopsis glabrata. Tioconazole prevents the growth and function of some fungal organisms by interfering with the production of substances needed to preserve the cell membrane. This drug is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections.
14-alpha Demethylase Inhibitors
Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism. (See all compounds classified as 14-alpha Demethylase Inhibitors.)
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
D - Dermatologicals
D01 - Antifungals for dermatological use
D01A - Antifungals for topical use
D01AC - Imidazole and triazole derivatives
D01AC07 - Tioconazole
G - Genito urinary system and sex hormones
G01 - Gynecological antiinfectives and antiseptics
G01A - Antiinfectives and antiseptics, excl. combinations with corticosteroids
G01AF - Imidazole derivatives
G01AF08 - Tioconazole
Absorption
Systemic absorption following a single intravaginal application of tioconazole in nonpregnant patients is negligible.
Orally administered tioconazole is extensively metabolized. The major metabolites are glucuronide conjugates.
Tioconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. In this way, tioconazole inhibits ergosterol synthesis, resulting in increased cellular permeability. Tioconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Solubilizers
Direct Compression
API Stability Enhancers
Topical
Lubricants & Glidants
Thickeners and Stabilizers
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Tioconazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tioconazole, including repackagers and relabelers. The FDA regulates Tioconazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tioconazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tioconazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tioconazole supplier is an individual or a company that provides Tioconazole active pharmaceutical ingredient (API) or Tioconazole finished formulations upon request. The Tioconazole suppliers may include Tioconazole API manufacturers, exporters, distributors and traders.
click here to find a list of Tioconazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tioconazole DMF (Drug Master File) is a document detailing the whole manufacturing process of Tioconazole active pharmaceutical ingredient (API) in detail. Different forms of Tioconazole DMFs exist exist since differing nations have different regulations, such as Tioconazole USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tioconazole DMF submitted to regulatory agencies in the US is known as a USDMF. Tioconazole USDMF includes data on Tioconazole's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tioconazole USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tioconazole suppliers with USDMF on PharmaCompass.
A Tioconazole CEP of the European Pharmacopoeia monograph is often referred to as a Tioconazole Certificate of Suitability (COS). The purpose of a Tioconazole CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Tioconazole EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Tioconazole to their clients by showing that a Tioconazole CEP has been issued for it. The manufacturer submits a Tioconazole CEP (COS) as part of the market authorization procedure, and it takes on the role of a Tioconazole CEP holder for the record. Additionally, the data presented in the Tioconazole CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Tioconazole DMF.
A Tioconazole CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Tioconazole CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Tioconazole suppliers with CEP (COS) on PharmaCompass.
A Tioconazole written confirmation (Tioconazole WC) is an official document issued by a regulatory agency to a Tioconazole manufacturer, verifying that the manufacturing facility of a Tioconazole active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tioconazole APIs or Tioconazole finished pharmaceutical products to another nation, regulatory agencies frequently require a Tioconazole WC (written confirmation) as part of the regulatory process.
click here to find a list of Tioconazole suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tioconazole as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tioconazole API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tioconazole as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tioconazole and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tioconazole NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tioconazole suppliers with NDC on PharmaCompass.
Tioconazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tioconazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tioconazole GMP manufacturer or Tioconazole GMP API supplier for your needs.
A Tioconazole CoA (Certificate of Analysis) is a formal document that attests to Tioconazole's compliance with Tioconazole specifications and serves as a tool for batch-level quality control.
Tioconazole CoA mostly includes findings from lab analyses of a specific batch. For each Tioconazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tioconazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Tioconazole EP), Tioconazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tioconazole USP).
LOOKING FOR A SUPPLIER?
